Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study [0.03%]
新冠大流行期间减肥手术后国际队列的30天结局研究（日内瓦研究）
Rishi Singhal,Abd A Tahrani,Christian Ludwig et al.
Rishi Singhal et al.
Talha Burki
Talha Burki
Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations [0.03%]
嗜铬细胞瘤与妊娠：展望更好的结果、减少恐惧和有价值的建议
Karel Pacak,David Taieb
Karel Pacak
Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature [0.03%]
嗜铬细胞瘤与妊娠的母胎结局：一项多中心回顾性队列研究及文献系统综述
Irina Bancos,Elizabeth Atkinson,Charis Eng et al.
Irina Bancos et al.
Background: Phaeochromocytoma or paraganglioma (collectively known as PPGL) in pregnant women can lead to severe complications and death due to associated catecholamine excess. We aimed to identify factors associated with...
Multicenter Study
The lancet. Diabetes & endocrinology. 2021 Jan;9(1):13-21. DOI:10.1016/S2213-8587(20)30363-6 2021
Feifei Cheng,Luke Carroll,Mugdha V Joglekar et al.
Feifei Cheng et al.
Telomeres are regions of repetitive nucleotide sequences at the ends of chromosomes. Telomere length is a marker of DNA damage, which is often considered a biomarker for biological ageing, and has also been linked with cardiovascular diseas...
Louise Davies,Jenny K Hoang
Louise Davies
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial [0.03%]
恩格列净对2型糖尿病伴动脉粥样硬化性心血管疾病患者首次和再次临床事件的影响：EMPA-REGOUTCOME试验的事后分析
Darren K McGuire,Bernard Zinman,Silvio E Inzucchi et al.
Darren K McGuire et al.
Background: Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascul...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2020 Dec;8(12):949-959. DOI:10.1016/S2213-8587(20)30344-2 2020